Skip to content
Clinical Trials – home
NorwayBack to Norway

Clinical trials in Moss

130 clinical trials in Moss, Norway. Every trial is listed in the EU Clinical Trials Register and updated daily.

NorwayOur site in NorwayKliniske-Studier.no(opens in a new tab)
Moss at a glance
130
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

130 trials in Moss

Open in trial search

Crohn's disease

Recruiting

Study of JNJ-78934804 (guselkumab and golimumab) versus guselkumab in adults with moderately to severely active Crohn’s disease

InvestigationalNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Golimumab
  • Sponsor:Janssen Cilag International

A Phase 3 Study of Orelabrutinib to Delay Disability Progression in Patients with Non‑Active Secondary Progressive Multiple Sclerosis

Investigational
Countries:NorwayNorway
  • Participants:18–64 years
  • Substances:Orelabrutinib
  • Sponsor:Zenas Biopharma (USA) LLC

Safety and Pharmacodynamics of RBD4059 and Apixaban in Patients with Non‑Valvular Atrial Fibrillation: A Randomized Active‑Controlled Study

Registered drug
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Apixaban
  • Sponsor:Ribocure Pharmaceuticals AB

Randomized Phase III trial of elecoglipron plus dapagliflozin on kidney outcomes and mortality in adults with chronic kidney disease

Registered drug
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:AZD5004
  • Sponsor:AstraZeneca AB

Phase 3 study of ZL-1310 versus topotecan hydrochloride in patients with relapsed small cell lung cancer

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:ZL-1310
  • Sponsor:Zai Lab (US) LLC

Study of vicadrostat and empagliflozin combination in patients with type 2 diabetes, high blood pressure and cardiovascular disease

Registered drug
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:BI 690517
  • Sponsor:Boehringer Ingelheim Espana S.A.

Study on Selatogrel for Preventing Heart Attack in Patients with Recent Heart Attack History

Investigational
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Selatogrel
  • Sponsor:Viatris Innovation GmbH

Crohn's disease

Recruiting

Study on the Effects of Zasocitinib for Patients with Moderate to Severe Crohn's Disease

Investigational
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Zasocitinib
  • Sponsor:Takeda Development Center Americas Inc.

Study on Clazakizumab for Heart Disease in Adults with End-Stage Kidney Disease on Dialysis

Investigational
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Clazakizumab
  • Sponsor:CSL Behring LLC

Study on the Safety and Effectiveness of EIK1001 and Pembrolizumab for Patients with Advanced Melanoma

Registered drug
Countries:NorwayNorway
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Eikon Therapeutics Inc.

Anaemia+1

Recruiting

A Phase 3 Study of Elritercept Versus Epoetin Alfa in ESA‑Naïve Adults with Lower‑Risk Myelodysplastic Syndrome Requiring Red Blood Cell Transfusions

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Elritercept
  • Sponsor:Takeda Development Center Americas Inc.

Study of LY3537982, pembrolizumab, and a drug combination for patients with advanced non-small cell lung cancer and a KRAS G12C mutation

Registered drug
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Eli Lilly & Co.

Other cities in Norway

The busiest research cities in the country

All 53 cities in Norway

Clinical research in Moss

What the registry says about research in the country

01 Rheumatology & Immunology

Clinical research focusing on giant cell arteritis (GCA), exploring innovative therapeutic approaches for this rare inflammatory blood vessel condition. The trials aim to evaluate new treatment combinations that could improve patient outcomes while optimizing glucocorticoid therapy regimens.

  • Inflammatory Vascular Disorders
  • Autoimmune Disease Management
  • Targeted Immunotherapy

These investigations are designed to assess the effectiveness of combining novel biological treatments with traditional steroid therapies, potentially offering new hope for patients managing chronic inflammatory conditions.

02 Therapeutic Innovation

Advanced studies evaluating combination therapy approaches that integrate biological agents with standardized glucocorticoid tapering protocols. This research aims to establish more effective treatment strategies while potentially reducing long-term steroid exposure.

  • Treatment Optimization
  • Steroid-Sparing Strategies
  • Long-term Disease Management

The research focuses on developing sustained remission protocols that could revolutionize the standard of care for inflammatory vascular conditions.

03 Clinical Outcomes

Comprehensive evaluation of treatment efficacy and safety in vascular inflammation, with particular attention to sustained disease remission. The research examines both immediate therapeutic responses and long-term outcomes in patients with inflammatory arterial disease.

  • Remission Assessment
  • Safety Monitoring
  • Quality of Life Impacts

These trials are designed to provide crucial data on the effectiveness of new therapeutic approaches in achieving and maintaining disease control.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.